Reshaping the future of early-stage cancer treatment

Our Individualized Neoantigen Therapeutic Vaccines (INTV) coming from myvac® platform are designed to prevent relapse in early-stage cancer
myvac® platform is based on the latest technological, genomic and medical innovations, while integrating artificial intelligence and bioinformatics to design therapies for each patient.
Our INTV stimulate a targeted immune response against the patient’s individual cancer with the aim of preventing disease relapse for early-stage patients with solid tumors.
One Patient • One Cancer • One Vaccine
Each myvac® product is designed to stimulate and educate the immune system against a patient’s cancer using tumor-specific genetic mutations (neoantigens) targeting each patients’ unique cancer.
These neoantigens are identified and selected through cutting edge Artificial Intelligence technologies. They are selected for their ability to induce an immune response expected to extend disease-free survival.
The selected neoantigens are integrated into the genome of our MVA viral vector, through our proprietary computational tool, VacDesignR®.
The treatment is produced on demand, for each patient in a unique in-house production unit that complies with GMP standards.
VacDesignR®: in-house computational design engine that optimizes recombinant plasmid architecture for MVA vectors

INTV Mechanism of Action
The mechanism of action of individualized therapeutic vaccines generated by the myvac® platform allows the patient’s own immune system to fight against their cancer.
These immunotherapies induce a cascade of immune reactions that lead to the production of T cells that will only destroy the targeted malignant cells. They are administered as a single agent in early-stage adjuvant therapy. The myvac® platform could be applied across a range of solid tumors where in many cases a significant unmet medical need remains.
Our Individualized Immunotherapies
TG4050, the first individualized therapeutic vaccine based on the myvac® demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers (HNSCC1) (NTC4183166).
Positive Phase 1 data, a Phase 2 part is currently underway in the same patient population.
The development of TG4050 is based on a strategic partnership between NEC and Transgene.
To learn more about TG4050
.
TG4070, a second individualized vaccine candidate derived from myvac®, is in Phase 1 clinical development in combination with nivolumab in adjuvant non-small lung cancer (NSCLC2) (EUCT 2025-520946-31-00).
Patient screening to start in coming weeks.
To learn more about TG4070
.
myvac® platform: Potential to reduce the risk of relapse across multiple operable solid tumors
.
